Mirum Pharmaceuticals (NASDAQ:MIRM) Given New $167.00 Price Target at Citizens Jmp

Mirum Pharmaceuticals (NASDAQ:MIRM) had its price objective boosted by analysts at Citizens Jmp from $144.00 to $167.00 in a note issued to investors on Wednesday, Benzinga reports. The firm presently has a “market outperform” rating on the stock. Citizens Jmp‘s target price indicates a potential upside of 91.89% from the company’s current price.

Other analysts have also recently issued research reports about the stock. Stifel Nicolaus increased their price target on shares of Mirum Pharmaceuticals from $136.00 to $156.00 and gave the company a “buy” rating in a research note on Wednesday, October 14th. HC Wainwright lifted their price target on shares of Mirum Pharmaceuticals from $200.00 to $202.00 and gave the company a “buy” rating in a research report on Wednesday. Wall Street Zen lowered Mirum Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Sunday, September 6th. Royal Bank Of Canada increased their price objective on Mirum Pharmaceuticals from $135.00 to $155.00 and gave the stock an “outperform” rating in a research report on Thursday, October 8th. Finally, Weiss Ratings downgraded Mirum Pharmaceuticals from a “sell (d)” rating to a “sell (d-)” rating in a research report on Thursday, October 22nd. One investment analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, Mirum Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus target price of $153.56.

Mirum Pharmaceuticals Stock Up 1.5%

NASDAQ MIRM opened at $87.03 on Wednesday. The business’s fifty day simple moving average is $89.53 and its 200-day simple moving average is $98.42. The company has a quick ratio of 2.74, a current ratio of 2.86 and a debt-to-equity ratio of 1.28. The firm has a market cap of $5.65 billion, a PE ratio of -5.98 and a beta of 0.75. Mirum Pharmaceuticals has a 52 week low of $63.23 and a 52 week high of $130.00.

Mirum Pharmaceuticals (NASDAQ:MIRM) last released its quarterly earnings data on Tuesday, November 3rd. The company reported ($0.87) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.49) by ($0.38). Mirum Pharmaceuticals had a negative return on equity of 36.28% and a negative net margin of 139.18%. The firm had revenue of $185.72 million for the quarter, compared to analyst estimates of $178.07 million. During the same quarter in the previous year, the business posted $0.05 earnings per share. Mirum Pharmaceuticals’s revenue for the quarter was up 39.6% on a year-over-year basis. As a group, equities analysts anticipate that Mirum Pharmaceuticals will post -1.32 earnings per share for the current year.

Insider Buying and Selling at Mirum Pharmaceuticals

In other news, SVP Jolanda Howe sold 658 shares of the business’s stock in a transaction that occurred on Wednesday, September 2nd. The shares were sold at an average price of $100.00, for a total value of $65,800.00. Following the sale, the senior vice president directly owned 616 shares of the company’s stock, valued at approximately $61,600. The trade was a 51.65% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Eric Bjerkholt sold 6,001 shares of the company’s stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $99.90, for a total transaction of $599,499.90. Following the completion of the transaction, the chief financial officer owned 36,355 shares in the company, valued at approximately $3,631,864.50. This represents a 14.17% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 96,659 shares of company stock worth $9,604,100 over the last three months. Insiders own 8.32% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of MIRM. Jupiter Topco LLC purchased a new stake in shares of Mirum Pharmaceuticals in the 2nd quarter valued at $691,672,000. Janus Henderson Group PLC boosted its holdings in Mirum Pharmaceuticals by 14.5% during the 1st quarter. Janus Henderson Group PLC now owns 6,945,813 shares of the company’s stock valued at $641,764,000 after acquiring an additional 880,505 shares during the period. BlackRock Inc. purchased a new position in Mirum Pharmaceuticals during the 2nd quarter valued at about $513,945,000. ABS Investment Management LLC acquired a new position in Mirum Pharmaceuticals in the 2nd quarter valued at about $245,847,000. Finally, William Blair Investment Management LLC acquired a new position in Mirum Pharmaceuticals in the 2nd quarter valued at about $164,453,000.

More Mirum Pharmaceuticals News

Here are the key news stories impacting Mirum Pharmaceuticals this week:

• Positive Sentiment: Revenue was $185.72 million, above estimates of about $178 million and up 39.6% year over year. Mirum Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Update
• Neutral Sentiment: Mirum said it would present new data across its rare liver disease portfolio at AASLD’s The Liver Meeting. The provided report does not detail the findings, so their potential impact is unclear. Mirum Pharmaceuticals Showcases Momentum Across Rare Liver Disease Portfolio
• Negative Sentiment: Mirum posted a quarterly loss of $0.87 per share, wider than analyst estimates of roughly $0.49–$0.53 per share and a reversal from earnings of $0.05 a year earlier. Mirum Pharmaceuticals Reports Q3 Loss, Tops Revenue Estimates

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing treatments for rare diseases, particularly disorders affecting the liver and bile acid pathways. The company’s medicines are designed to address conditions with limited treatment options and to improve outcomes for children and adults living with serious chronic diseases.

Mirum’s lead product is LIVMARLI (maralixibat), an oral bile acid transport inhibitor used to treat cholestatic pruritus, or severe itching caused by impaired bile flow, in patients with Alagille syndrome and progressive familial intrahepatic cholestasis.